Clinical Trials Logo

Clinical Trial Summary

The goal of this study will aim to determine if adding phenobarbital or ketamine to a symptom-triggered benzodiazepine regimen decreases the rate of intensive care unit admissions during the treatment of alcohol withdrawal syndrome when compared to symptom-triggered benzodiazepine therapy alone.


Clinical Trial Description

The primary objective of this study is to compare phenobarbital and ketamine adjunctive therapies to lorazepam-based therapy in the treatment of acute alcohol withdrawal syndrome.

It is hypothesized that the use of an alternative agent, either phenobarbital or ketamine, when used as an adjunct to symptom-triggered lorazepam therapy will significantly reduce the rate of intensive care unit admissions and thereby reduce the total cost associated with hospital admission for treatment of alcohol withdrawal syndrome.

Enrolled patients will be admitted to Santa Barbara Cottage Hospital where they will be monitored with continuous pulse oximetry and cardiac telemetry. They will remain hospitalized while undergoing study-guided therapy in addition to supportive care for acute alcohol withdrawal syndrome. Patients will undergo standard of care therapy with lorazepam symptom-triggered therapy regardless of study participation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03788889
Study type Interventional
Source Santa Barbara Cottage Hospital
Contact
Status Withdrawn
Phase Phase 4
Start date April 12, 2019
Completion date April 12, 2019

See also
  Status Clinical Trial Phase
Completed NCT03033823 - MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA) Phase 3
Completed NCT02146716 - Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms. N/A
Completed NCT01637415 - The "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS) N/A
Completed NCT04973202 - Portrayal of Hospital Alcohol Detoxification in France
Terminated NCT02052440 - Preventing Alcohol Withdrawal Syndrome With Oral Baclofen Phase 3
Completed NCT01652326 - Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome N/A
Recruiting NCT03235531 - Assessment of Valproate on Ethanol Withdrawal Phase 4
Completed NCT00146471 - Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome Phase 3
Completed NCT02090504 - Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome Phase 4
Completed NCT03012815 - Gabapentin for Alcohol Withdrawal Syndrome Phase 4
Completed NCT05438641 - Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants
Completed NCT00249366 - Treatment of Alcohol Withdrawal in Hospital Patients Phase 4